Small cell carcinoma of the urinary bladder - Revision history

Michael: /* Microscopic */

2022-05-17T21:25:09Z

Microscopic

← Older revision		Revision as of 21:25, 17 May 2022
Line 45:		Line 45:
	Features:		Features:
	*Cohesive small cells (~2x resting lymphocytes) with scant cytoplasm - see ''[[small cell carcinoma]]''.		*Cohesive small cells (~2x resting lymphocytes) with scant cytoplasm - see ''[[small cell carcinoma]]''.
	**May have nuclear moulding.		*+/-Nuclear moulding.
	*If mixed histology with urothelial carcinoma, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.<ref>{{Ref WHOGU2016\|117-8}}</ref>		*If mixed histology with urothelial carcinoma, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.<ref>{{Ref WHOGU2016\|117-8}}</ref>

Michael: /* Microscopic */

2022-05-17T21:24:51Z

Microscopic

← Older revision		Revision as of 21:24, 17 May 2022
Line 44:		Line 44:
	==Microscopic==		==Microscopic==
	Features:		Features:
	*~~See~~ ''[[small cell carcinoma]]''.		*Cohesive small cells (~2x resting lymphocytes) with scant cytoplasm - see ''[[small cell carcinoma]]''.
	*If mixed histology, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.<ref>{{Ref WHOGU2016\|117-8}}</ref>		**May have nuclear moulding.
			*If mixed histology with urothelial carcinoma, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.<ref>{{Ref WHOGU2016\|117-8}}</ref>

	Note:		Note:
Line 51:		Line 52:

	DDx:		DDx:
			*[[Urothelial carcinoma]] with a small cell carcinoma component
	*[[Small cell carcinoma of the prostate gland]].		*[[Small cell carcinoma of the prostate gland]].
	*[[Lymphoma]], large cell.		*[[Lymphoma]], large cell.

Michael at 21:23, 17 May 2022

2022-05-17T21:23:02Z

← Older revision		Revision as of 21:23, 17 May 2022
Line 5:		Line 5:
	\| Caption = [[Small cell carcinoma]] of the urinary bladder. [[H&E stain]].		\| Caption = [[Small cell carcinoma]] of the urinary bladder. [[H&E stain]].
	\| Synonyms =		\| Synonyms =
	\| Micro =		\| Micro = small cohesive cells with scant cytoplasm, nuclear moulding
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[small cell carcinoma of the prostate gland]], [[lymphoma]] (large cell), other [[small round blue cell tumours]]		\| LMDDx = [[small cell carcinoma of the prostate gland]], [[lymphoma]] (large cell), other [[small round blue cell tumours]], [[urothelial carcinoma]] with a small cell carcinoma component
	\| Stains = [[pankeratin]] +ve, chromogranin +ve, synaptophysin +ve, [[CD56]] +ve		\| Stains = [[pankeratin]] +ve, chromogranin +ve, synaptophysin +ve, [[CD56]] +ve
	\| IHC =		\| IHC =

Michael: /* Microscopic */

2022-05-17T21:20:53Z

Microscopic

← Older revision		Revision as of 21:20, 17 May 2022
Line 45:		Line 45:
	Features:		Features:
	*See ''[[small cell carcinoma]]''.		*See ''[[small cell carcinoma]]''.
	*If mixed histology, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.		*If mixed histology, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.<ref>{{Ref WHOGU2016\|117-8}}</ref>

	Note:		Note:

Michael: /* Microscopic */

2022-05-17T21:18:47Z

Microscopic

← Older revision		Revision as of 21:18, 17 May 2022
Line 45:		Line 45:
	Features:		Features:
	*See ''[[small cell carcinoma]]''.		*See ''[[small cell carcinoma]]''.
			*If mixed histology, ''small cell carcinoma'' component must be majority of tumour; otherwise classified as ''urothelial carcinoma with small cell carcinoma component''.

	Note:		Note:

Michael: /* IHC */

2021-06-30T14:13:58Z

IHC

← Older revision		Revision as of 14:13, 30 June 2021
Line 66:		Line 66:
	*Synaptophysin +ve.		*Synaptophysin +ve.
	*[[CD56]] +ve.		*[[CD56]] +ve.
			*TTF-1 +ve/-ve.

	==Sign out==		==Sign out==

Michael: /* Sign out */ tweak

2021-06-30T14:13:23Z

Sign out: tweak

← Older revision		Revision as of 14:13, 30 June 2021
Line 74:		Line 74:

	Comment:		Comment:
	The tumour consists of cohesive~~, moulded~~, small blue cells with necrosis. There is no definite urothelial differentiation, and no other differentiation to suggest a particular primary site.		The tumour consists of cohesive, small blue cells with nuclear moulding and necrosis. There is no definite urothelial differentiation, and no other differentiation to suggest a particular primary site.

	The tumour stains as follows:		The tumour stains as follows:

Michael: +SO

2021-06-30T14:07:40Z

+SO

← Older revision		Revision as of 14:07, 30 June 2021
Line 66:		Line 66:
	*Synaptophysin +ve.		*Synaptophysin +ve.
	*[[CD56]] +ve.		*[[CD56]] +ve.

			==Sign out==
			<pre>
			Urinary Bladder Tumour, Transurethral Resection:
			- SMALL CELL CARCINOMA, invades muscularis propria, see comment.
			-- Please see synoptic report.

			Comment:
			The tumour consists of cohesive, moulded, small blue cells with necrosis. There is no definite urothelial differentiation, and no other differentiation to suggest a particular primary site.

			The tumour stains as follows:
			POSITIVE: CK7 (dot-like moderate, diffuse), chromogranin A (moderate, diffuse), synaptophysin (strong, diffuse), TTF-1 (strong, diffuse).
			NEGATIVE: CK20, CD45 (lymphocytes in background), CD20, PSA, p63 (marks benign urothelium).
			PROLIFERATION (Ki-67): >90%.

			Small cell carcinoma of the urinary bladder is the main consideration, based the anatomical site of the specimen. The findings above should be considered in the context of the imaging and clinical history.
			</pre>

	==See also==		==See also==

Michael at 21:31, 1 August 2016

2016-08-01T21:31:07Z

← Older revision		Revision as of 21:31, 1 August 2016
Line 8:		Line 8:
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[small cell carcinoma of the prostate gland]], [[lymphoma]] (large cell), other [[small round blue cell tumours]]		\| LMDDx = [[small cell carcinoma of the prostate gland]], [[lymphoma]] (large cell), other [[small round blue cell tumours]]
	\| Stains = pankeratin +ve, chromogranin +ve, synaptophysin +ve, CD56 +ve		\| Stains = [[pankeratin]] +ve, chromogranin +ve, synaptophysin +ve, [[CD56]] +ve
	\| IHC =		\| IHC =
	\| EM =		\| EM =
Line 62:		Line 62:

	==IHC==		==IHC==
	*~~Pankeratin~~ +ve,		*[[Pankerati]]n +ve,
	*Chromogranin +ve.		*Chromogranin +ve.
	*Synaptophysin +ve.		*Synaptophysin +ve.
	*CD56 +ve.		*[[CD56]] +ve.

	==See also==		==See also==

Michael at 03:25, 6 January 2014

2014-01-06T03:25:29Z

← Older revision		Revision as of 03:25, 6 January 2014
Line 33:		Line 33:

	==General==		==General==
	*Very rare.<ref name=pmid24168010>{{Cite journal \| last1 = Koga \| first1 = F. \| last2 = Yokoyama \| first2 = M. \| last3 = Fukushima \| first3 = H. \| title = Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments. \| journal = Expert Rev Anticancer Ther \| volume = 13 \| issue = 11 \| pages = 1269-79 \| month = Nov \| year = 2013 \| doi = 10.1586/14737140.2013.851605 \| PMID = 24168010 }}</ref>		*Very rare<ref name=pmid24168010>{{Cite journal \| last1 = Koga \| first1 = F. \| last2 = Yokoyama \| first2 = M. \| last3 = Fukushima \| first3 = H. \| title = Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments. \| journal = Expert Rev Anticancer Ther \| volume = 13 \| issue = 11 \| pages = 1269-79 \| month = Nov \| year = 2013 \| doi = 10.1586/14737140.2013.851605 \| PMID = 24168010 }}</ref> - less than 1% of bladder cancers in one series.<ref name=pmid24009428>{{Cite journal \| last1 = Hou \| first1 = CP. \| last2 = Lin \| first2 = YH. \| last3 = Chen \| first3 = CL. \| last4 = Chang \| first4 = PL. \| last5 = Tsui \| first5 = KH. \| title = Clinical outcome of primary small cell carcinoma of the urinary bladder. \| journal = Onco Targets Ther \| volume = 6 \| issue = \| pages = 1179-85 \| month = \| year = 2013 \| doi = 10.2147/OTT.S49879 \| PMID = 24009428 }}</ref>
	*Poor prognosis.<ref name=~~pmid24168010~~/>		*Poor prognosis<ref name=pmid24168010/> - survival ~ 11 months.<ref name=pmid24009428/>

			Clinical:
			*Hematuria - typical presentation.<ref name=pmid24009428/>

			Epidemiology:
			*[[Smoking]] - very common.<ref name=pmid24009428/>

	==Microscopic==		==Microscopic==
	Features:		Features:
	*See ''[[small cell carcinoma]]''.		*See ''[[small cell carcinoma]]''.

			Note:
			*Usually co-exists with [[urothelial carcinoma]] ~60% of cases in one series.<ref name=pmid24009428/>

	DDx:		DDx: